TENIDAP

Tenidap is the first of a new class of agents with anti-inflammatory a nd immunomodulatory activity in rheumatoid arthritis It is a cytokine modulator and reduces production of certain proinflammatory cytokines including interleukins-1 and -6 and tumour necrosis factor-alpha It al so inhibits cyclo-oxygenase, decreasing the production of proinflammat ory arachidonic acid derivatives Parameters of disease control (grip s trength, number of tender/swollen joints, pain, erythrocyte sedimentat ion rate, acute phase protein levels) in patients with rheumatoid arth ritis were improved with tenidap therapy Tenidap was more effective th an representative nonsteroidal anti-inflammatory drugs (NSAIDs) as tre atment for rheumatoid arthritis Tenidap was at least as effective as c ombination therapy with NSAIDs and disease modifying antirheumatic dru gs as treatment for rheumatoid arthritis.